CS
ACAD icon

Credit Suisse’s Acadia Pharmaceuticals ACAD Stock Holding History

Credit Suisse’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-40,000
Closed -$990K – 4566
2014
Q3 		$990K Sell
40,000
-492,800
-92% -$11.5M ﹤0.01% 3051
2014
Q2 		$12M Sell
532,800
-561,200
-51% -$11.7M 0.01% 1258
2014
Q1 		$26.6M Buy
1,094,000
+236,600
+28% +$5.99M 0.03% 691
2013
Q4 		$21.4M Buy
+857,400
New +$20.2M 0.02% 798

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Credit Suisse's ACAD Position: Q1 2024 in Review

Credit Suisse increased its Acadia Pharmaceuticals (ACAD) stake by 0.66% in Q1 2024, buying an estimated $22.8K and bringing the position to 141,343 shares worth $2.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1681.

Credit Suisse first reported a position in ACAD in Q2 2013 and has held it in 44 quarters since. The position peaked at $14.5M in Q2 2020. 268 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • Credit Suisse held 141,343 shares of Acadia Pharmaceuticals worth $2.61M as of Q1 2024.
  • Credit Suisse bought 921 Acadia Pharmaceuticals shares in Q1 2024, an estimated $22.8K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1681 holding.
  • Credit Suisse first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Acadia Pharmaceuticals position peaked at $14.5M in Q2 2020.
  • 268 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.